Skip to content

Trial Summary

This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers.



ACTRN/NCT /ethics:


Scientific title:

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Sponsor / Cooperative group:

Zymeworks Inc.

Trial & Patient Characteristics

Cancer TypeHER2-expressing Cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Advanced
Anticipated Start Date2016-09-01
Anticipated End Date2023-08-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlison Richards
Phone08 8206 4835
Principal InvestigatorDr Amitesh Roy
Recruitment StatusRecruiting